Last Posted: Feb 14, 2020
- CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction
P Vaidya et al, Lancet Digital Health, February 13, 2020 - DNA amount comparison between cytologic and histologic samples for epithelial growth factor receptor (EGFR) testing in non-small-cell lung cancer (NSCLC) patients: a single institution experience.
Gobbini E et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Oct 28 Suppl 6vi58 - Biomarkers in Lung Cancer.
Sears Catherine R et al. Clinics in chest medicine 2020 Mar 41(1) 115-127 - Circulating tumor DNA analysis in the era of precision oncology.
Said Rabih et al. Oncotarget 2020 Jan 11(2) 188-211 - Feature-shared adaptive-boost deep learning for invasiveness classification of pulmonary sub-solid nodules in CT images.
Wang Jun et al. Medical physics 2020 Feb - Genetic alteration profile of EGFR -mutant resected IIB-IIIA stage NSCLC and correlation to clinical outcomes.
Deng Qiuhua et al. Translational lung cancer research 2019 Dec 8(6) 838-846 - Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity.
van den Broek Daan et al. Frontiers in oncology 2019 91521 - Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients.
Jiang Ruirui et al. Scientific reports 2020 Feb 10(1) 2070 - Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.
Leung Maria et al. Cancer 2020 Jan - Improving Clinical Trial Participant Prescreening With Artificial Intelligence (AI): A Comparison of the Results of AI-Assisted vs Standard Methods in 3 Oncology Trials.
Calaprice-Whitty Denise et al. Therapeutic innovation & regulatory science 2020 Jan 54(1) 69-74
.png)
No hay comentarios:
Publicar un comentario